Work package 6 – Preparation and conduct of phase I clinical trial

The main objective of this work package is to assess the safety and immunogenicity of the selected vaccine candidate in a phase I clinical trial.  The specific objectives are:

  • GMP manufacturing and stability studies of the selected MV-ZIKA vaccine candidate
  • Toxicity study in non-human primates
  • Preparation and conduct of the phase I clinical trial

Partners involved:

Themis Bioscience (work package leader)

European Vaccine Initiative (EVI)